Study on Pembrolizumab for Patients with Early-Stage NK/T-cell Lymphoma, Nasal Type

Inclusion Criteria

• Diagnosed with extranodal NK/T-cell lymphoma, nasal type.
• At least 18 years old.
• In good general health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have measurable disease as shown by PET/CT scans.
• Have good kidney function, with creatinine levels within normal limits or a creatinine clearance of at least 60 mL/min.
• Have good liver function, with bilirubin and liver enzyme levels within specified limits.
• Have a heart ejection fraction of at least 50%.
• Have adequate lung function.
• Women of childbearing potential must have a negative pregnancy test before starting the study and agree to use effective contraception during the study and for 120 days after the last dose.
• Men must agree to use effective contraception during the study and for 120 days after the last dose.

Exclusion Criteria

• Have received any prior treatment for extranodal NK/T-cell lymphoma.
• Have other medical conditions that make participation in the study inappropriate.
• Have received a live vaccine within 30 days before starting the study drug.
• Have another active cancer that is progressing or has needed treatment in the past 2 years, except for certain skin cancers or carcinoma in situ.
• Have cancer that has spread to the brain or spinal cord.
• Have severe allergies to pembrolizumab or its ingredients.
• Have an active autoimmune disease needing treatment in the past 2 years.
• Have a history of lung inflammation needing steroids or current lung inflammation.
• Have an active infection needing treatment.
• Have a history of HIV.
• Have active Hepatitis B or C.
• Have any condition or treatment that might interfere with the study results or participation.
• Have psychiatric or substance abuse issues that would interfere with the study.
• Are pregnant, breastfeeding, or planning to conceive or father a child during the study and for 120 days after the last dose.
• Have had a tissue or organ transplant.